Prevention or Prescription? The Alzheimer’s Debate We’re Avoiding
If doctors can’t agree on what defines Alzheimer's, what are we expecting a pharmaceutical “cure” to fix? We’re chasing a silver bullet for a target we haven’t clearly defined.
A recent Wall Street Journal article laid that out clearly. Doctors and researchers don’t agree on what constitutes an Alzheimer’s diagnosis. And given that monoclonal antiamyloid antibody therapy can have serious side effects like brain hemorrhages and bleeding (not to mention the expense), it’s a pretty big deal.
The disagreements relate to what factors must be present to constitute a diagnosis: Amyloid proteins alone, or amyloid, Tau, and cognitive symptoms. The latter, of course, is very subjective.
Focusing on Prevention
Meanwhile, research suggests that up to half of dementia cases could be prevented by addressing modifiable risk factors. But prevention doesn’t generate headlines. Or billion-dollar drug launches. Or soaring stock prices.
We say we want a cure. What we actually need—right now—is scale, access, and accountability around prevention. While the industry debates definitions and pipelines, at Mindr.us, we’re focused on making risk reduction practical, affordable, and available to the people who can benefit today.
The Mindr program is based on the Finnish FINGER trial and subsequent U.S. research, which show that consistent interventions and coaching are effective.
We've translated the research into practical daily activities that fit your life. It’s an affordable, personalized approach.
Take charge of your brain health today with a personalized Mindr plan. Sign up (1st two weeks are free) and start making informed changes that could make a real difference.
